Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10531MR)

This product GTTS-WQ10531MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Heterozygous familial hypercholesterolemia (HeFH) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ10531MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13354MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-06801591
GTTS-WQ12261MR IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MRA
GTTS-WQ12435MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA NI-0501
GTTS-WQ6980MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ETI-204
GTTS-WQ2126MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ALD-403
GTTS-WQ11022MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MCLA-117
GTTS-WQ13784MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-1033
GTTS-WQ3627MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 1179470
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW